Actualités

Nanocyclix portfolio - R&D pipeline
Communiqué de Presse
14/06/2021

Parkinson’s disease: Servier x Oncodesign announce the selection of a preclinical candidate

Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
18/05/2021

InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.

Lire la suite
Ressources presse
29/01/2021

[FR] Biotech Info – Oncodesign, la médecine de précision en ligne de mire

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
03/11/2020

Oncodesign announces Drug Discovery Cooperation with ViraTherapeutics, a Boehringer Ingelheim subsidiary

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
06/10/2020

Oncodesign obtains €15.9 million of non-dilutive financing in the form of a State-Guaranteed Loan within the context of the COVID-19 pandemic

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
10/09/2020

Oncodesign announces a capital increase reserved for the Company’s Management Committee

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
20/05/2020

Oncodesign and HitGen announce a strategic partnership in Integrated Drug Discovery Services (IDDS)

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
20/04/2020

Oncodesign announces the creation of its new “Artificial Intelligence” Business Unit and appoints Stéphane Gerart as its Head

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
17/02/2020

Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
17/12/2019

Oncodesign announces the selection of its First-in-Class RIPK2 inhibitor drug candidate for auto-immune and inflammatory diseases

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
24/10/2019

Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)

Lire la suite
Ressources presse
26/06/2019

[FR] Oncodesign a peut-être découvert la molécule qui va lui faire retrouver les faveurs de la Bourse

Lire la suite